Parkinson Disease

Etiology and Clinical Context

Etiology and neuropathology

Parkinson disease is a progressive neurodegenerative synucleinopathy characterized by degeneration of dopaminergic neurons in the substantia nigra pars compacta and pathologic accumulation of misfolded alpha-synuclein. Etiology is multifactorial: aging, genetic susceptibility, and environmental exposures contribute. Dopaminergic loss reduces striatal dopamine availability, disrupting basal ganglia loops that normally facilitate desired movement and suppress competing motor programs (Shakkottai & Lomen-Hoerth, 2019).

Epidemiologic context and interpretation

Parkinson disease becomes more common with advancing age but may present earlier, especially in individuals with relevant genetic susceptibility (Shakkottai & Lomen-Hoerth, 2019). Age at onset, environmental and medication exposures, family history, and asymmetric versus symmetric progression influence diagnostic probability. Age-related frequency does not establish idiopathic Parkinson disease in a patient whose examination instead suggests drug-induced or atypical parkinsonism.

Pathophysiology

Circuit dysfunction

In the classic basal ganglia model, dopamine promotes movement through D1-mediated direct-pathway facilitation and D2-mediated reduction of indirect-pathway inhibition. Dopamine deficiency increases inhibitory output from basal ganglia output nuclei to thalamocortical motor pathways, contributing to bradykinesia and impaired movement initiation. Tremor mechanisms involve broader oscillatory networks and are not fully explained by a simple dopamine-deficiency model. Widespread neurodegeneration and autonomic involvement also help explain nonmotor symptoms (Shakkottai & Lomen-Hoerth, 2019).

Clinical Manifestations

Bradykinesia, accompanied by rest tremor and/or rigidity, establishes clinical parkinsonism (Postuma et al., 2015). Parkinson disease often begins asymmetrically; associated findings include reduced arm swing, hypomimia, micrographia, hypophonia, shuffling gait, and later postural instability. Prodromal or associated nonmotor features include constipation, hyposmia, REM sleep behavior disorder, depression, orthostatic hypotension, urinary symptoms, sleep disruption, and cognitive changes. Early recurrent falls, prominent early autonomic failure, vertical gaze palsy, or poor levodopa responsiveness suggest an atypical parkinsonian syndrome.

Nonmotor disease and atypical features

Lewy pathology and associated degeneration affect more than nigrostriatal dopaminergic neurons (Shakkottai & Lomen-Hoerth, 2019). Constipation, impaired olfaction, REM sleep behavior disorder, neuropsychiatric symptoms, orthostatic hypotension, urinary symptoms, dysphagia, and cognition may appear before or alongside motor features. Early severe postural instability, rapidly progressive gait failure, pronounced autonomic dysfunction, or vertical gaze palsy suggests another diagnosis or mixed pathology. Multiple system atrophy may include prominent autonomic failure and cerebellar or parkinsonian findings. Progressive supranuclear palsy may include early falls and impaired vertical eye movements. Dementia with Lewy bodies has characteristic cognitive, neuropsychiatric, and movement features; the temporal relationship between dementia and parkinsonism is diagnostically relevant.

Diagnostic Evaluation

Diagnosis is principally clinical, based on cardinal findings, time course, associated features, and examination for atypical signs or drug-induced parkinsonism (Postuma et al., 2015). A meaningful levodopa response supports but does not independently confirm the diagnosis. Brain imaging is used when the presentation is atypical or structural disease is suspected; dopamine transporter imaging may help in selected diagnostically uncertain cases, but it does not reliably differentiate Parkinson disease from all atypical neurodegenerative parkinsonian syndromes.

Clinical diagnosis: what supports and what challenges idiopathic Parkinson disease

Bradykinesia is central to identifying parkinsonism: look for decrement in speed or amplitude during repetitive finger tapping, hand opening, or foot tapping (Shakkottai & Lomen-Hoerth, 2019). Rest tremor and rigidity support the syndrome, but an isolated action tremor without bradykinesia may represent essential tremor or another diagnosis. Typical idiopathic Parkinson disease often begins asymmetrically, evolves gradually, and may show a sustained response to dopaminergic therapy. Early unexplained falls, prominent early autonomic failure, vertical gaze limitation, cerebellar signs, or disproportionate early cognitive impairment should prompt consideration of progressive supranuclear palsy, multiple-system atrophy, corticobasal syndrome, Lewy body disease, vascular causes, or medication-induced parkinsonism. Structural imaging assists when atypical or focal findings suggest another process; it does not independently diagnose idiopathic disease.

Ask about dopamine-blocking antipsychotics, antiemetics, and other exposures before assuming degeneration of the substantia nigra (Postuma et al., 2015). Clinically significant nonmotor burden may include constipation, REM sleep behavior symptoms, orthostatic hypotension, mood changes, hallucinations, sleep fragmentation, swallowing impairment, and dysautonomia. These symptoms influence functional stage and the safe choice of therapy.

Operational diagnosis: establish parkinsonism before assigning Parkinson disease

The Movement Disorder Society clinical criteria begin by establishing parkinsonism: bradykinesia with rest tremor or rigidity. Bradykinesia is not simply slowness; examination looks for progressive reduction in amplitude or speed during repetitive movements. Once the syndrome is established, supportive findings, absolute exclusions, and diagnostic red flags determine whether idiopathic Parkinson disease is plausible. A convincing levodopa response and an asymmetric limb rest tremor support the diagnosis, but neither overrides a finding that strongly suggests an alternative process (Postuma et al., 2015).

Examples of findings that should change the formulation include vertical supranuclear gaze palsy or early recurrent falls (consider progressive supranuclear palsy), severe early autonomic failure or cerebellar signs (consider multiple system atrophy), cortical sensory loss or apraxia (consider corticobasal degeneration), and onset closely linked to dopamine-receptor blocking drugs (consider medication-induced parkinsonism). Dopamine-transporter imaging can support a presynaptic dopaminergic deficit when the syndrome is uncertain; an abnormal scan cannot reliably separate Parkinson disease from multiple system atrophy or progressive supranuclear palsy. The distinction is between meeting criteria for parkinsonism and establishing its cause (Postuma et al., 2015; Shakkottai & Lomen-Hoerth, 2019).

Treatment and Management

Treatment and mechanism

Levodopa, administered with a peripheral dopa-decarboxylase inhibitor such as carbidopa, replenishes CNS dopamine and is typically the most effective symptomatic intervention for bradykinesia and rigidity (Shakkottai & Lomen-Hoerth, 2019). Dopamine agonists, monoamine oxidase-B inhibitors, and catechol-O-methyltransferase inhibitors modify dopaminergic signaling in selected patients but introduce different adverse-effect risks. Over time, wearing-off and dyskinesias may develop as buffering capacity declines. Exercise, physical and occupational therapy, speech/swallow services, fall prevention, medication reconciliation, and nonmotor symptom management remain essential. Deep brain stimulation may be considered for appropriately selected patients with medication-responsive motor complications.

Treat the dominant disability while monitoring treatment-created harms

Levodopa replenishes CNS dopamine after conversion and often improves bradykinesia and rigidity; its timing and meal interactions matter clinically (Shakkottai & Lomen-Hoerth, 2019). Dopamine agonists can affect motor symptoms but may contribute to impulse-control behaviors, sleep attacks, hallucinations, orthostasis, or edema. Adjunctive inhibition of dopamine breakdown or peripheral metabolism may reduce motor fluctuations but can intensify dyskinesia or medication adverse effects. A patient with troublesome dyskinesias and peak-dose benefit needs a different adjustment strategy than one experiencing predictable end-of-dose wearing off. Rehabilitation, fall-risk review, speech/swallowing support, exercise, and attention to cognition remain essential regardless of pharmacologic regimen.

Mechanism-based treatment decisions and inpatient safety

In early symptomatic disease, the dominant functional deficit, cognition, orthostasis, hallucination history, occupational demands, and medication adverse-effect vulnerability should influence treatment choice. Levodopa restores dopamine precursor availability and is often the strongest intervention for bradykinesia; dopamine agonists stimulate receptors directly but carry risks of impulse-control disorders, hallucinations, edema, and daytime sleep attacks. Later, predictable wearing-off suggests waning benefit before the next dose, while peak-dose dyskinesia implicates excessive dopaminergic effect at a different point in the dosing cycle. These require different adjustments, and neither indicates that disease progression has stopped (Shakkottai & Lomen-Hoerth, 2019).

Care transitions introduce additional hazards: delayed or omitted scheduled antiparkinsonian medication may worsen mobility, swallowing, and rigidity, while dopamine-blocking antiemetics or antipsychotics can aggravate parkinsonism. Clinicians should reconcile exact administration timing and evaluate dysphagia, fall risk, orthostatic symptoms, delirium, and aspiration risk during acute illness. Therapy that reduces tremor but substantially worsens cognition or orthostasis may be a poor net choice. These medication principles are mechanistic educational guidance, not a substitute for current dosing protocols or movement-disorder consultation (Shakkottai & Lomen-Hoerth, 2019).

Clinical Reasoning Priorities

Applied case: tremor with changing function

A 71-year-old reports unilateral resting tremor, smaller handwriting, rigidity, constipation, and increasingly slow dressing. Bradykinesia plus characteristic associated findings raises Parkinson disease more strongly than tremor alone. Evaluate orthostasis, dopamine-blocking medicines, sleep, cognition, and falls. Levodopa increases central dopamine availability, but hallucinations or impulse-control problems associated with dopaminergic treatment can limit its use. Early recurrent falls or vertical gaze impairment should redirect the differential toward atypical parkinsonism.

Related YourDNP Guides

For related clinical reasoning, see Motor Neuron Diseases and Dementia and Neurocognitive Disorders.

• Back to Pathophysiology
• Gastroparesis
• Pharmacodynamics

---

---

References

Postuma, R. B., Berg, D., Stern, M., Poewe, W., Olanow, C. W., Oertel, W., Obeso, J., Marek, K., Litvan, I., Lang, A. E., Halliday, G., Goetz, C. G., Gasser, T., Dubois, B., Chan, P., Bloem, B. R., Adler, C. H., & Deuschl, G. (2015). MDS clinical diagnostic criteria for Parkinson’s disease. Movement Disorders, 30(12), 1591–1601. https://doi.org/10.1002/mds.26424

Shakkottai, V. G., & Lomen-Hoerth, C. (2019). Nervous system disorders. In G. D. Hammer & S. J. McPhee (Eds.), Pathophysiology of disease: An introduction to clinical medicine (8th ed.). McGraw-Hill Education.